EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genetic Aspects of Conjunctival Melanoma: A Review

Emily Chang, Hakan Demirci, F Yesim Demirci

Genes · 23.08.2023 · 14 (9) · 1668

DOI: 10.3390/genes14091668 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 23.08.2023. Verfasst von Emily Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI 48105, USA. Hauptthemen laut MEDLINE: Conjunctival Neoplasms, Melanoma, Bone Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Richard N, Marilyn K Witham.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conjunctival melanoma (CM) is a rare but aggressive cancer. Over the past decade, molecular studies using rapidly advancing technologies have increasingly improved our understanding of CM genetics. CMs are mainly characterized by dysregulated MAPK and PI3K/AKT/mTOR pathways, driven by commonly mutated (BRAF, NRAS, NF1) or less commonly mutated (KIT, PTEN) genes. Another group of genes frequently mutated in CMs include TERT and ATRX, with known roles in telomere maintenance and chromatin remodeling/epigenetic regulation. Uveal melanoma-related genes (BAP1, SF3B1, GNAQ/11) can also be mutated in CMs, albeit infrequently. Additional CM-related mutated genes have increasingly been identified using more comprehensive genetic analyses, awaiting further confirmation in additional/larger studies. As a tumor arising in a partly sun-exposed mucosal tissue, CM exhibits a distinct genomic profile, including the frequent presence of an ultraviolet (UV) signature (and high mutational load) and also the common occurrence of large structural variations (distributed across the genome) in addition to specific gene mutations. The knowledge gained from CM genetic studies to date has led to new therapeutic avenues, including the use of targeted and/or immuno-therapies with promising outcomes in several cases. Accordingly, the implementation of tumor genetic testing into the routine clinical care of CM patients holds promise to further improve and personalize their treatments. Likewise, a growing knowledge of poor prognosis-associated genetic changes in CMs (NRAS, TERT, and uveal melanoma signature mutations and chromosome 10q deletions) may ultimately guide future strategies for prognostic testing to further improve clinical outcomes (by tailoring surveillance and considering prophylactic treatments in patients with high-risk primary tumors).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conjunctival NeoplasmsMelanomaBone NeoplasmsUveal NeoplasmsHumansFemaleChromosome DeletionEpigenesis, GeneticPhosphatidylinositol 3-KinasesUveal Melanoma

Stichwörter der Autor:innen

UV signatureconjunctival melanomacopy number alterationsgenesgeneticmolecularmutationspathwaysstructural variationstumor mutational burden

Substanzen

Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI 48105, USA.
  • Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Förderung

  • Richard N
  • Marilyn K Witham

Zitieren

APA

Chang, E., Demirci, H., & Demirci, F. Y. (2023). Genetic Aspects of Conjunctival Melanoma: A Review. Genes, 14(9), 1668. https://doi.org/10.3390/genes14091668

Vancouver

Chang E, Demirci H, Demirci FY. Genetic Aspects of Conjunctival Melanoma: A Review. Genes. 2023;14(9):1668. doi:10.3390/genes14091668

BibTeX
@article{Chang2023,
  author = {Chang, Emily and Demirci, Hakan and Demirci, F Yesim},
  title = {Genetic Aspects of Conjunctival Melanoma: A Review},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {9},
  pages = {1668},
  doi = {10.3390/genes14091668}
}
Kostenlos starten →